Personalized cell therapy - for all cancers.

SeqCure Immunology is a Stockholm-based company that develops SeqCureNEO, a personalized cell therapy product for the treatment of advanced-stage cancer.
‍
The SeqCure^NEO product is created from the patient's own immune cells, isolated from a blood sample. Through our proprietary culturing process, the cells are cultured and modified to react against the patient's individual tumor mutations. No genetic engineering - only enrichment and strengthening of the weak anti-tumor immune response that already exists in the patient.

SeqCure Immunology is currently seeking investors to fund the final pre-clinical developement of SeqCureNEO in preparation for its First-In-Man clinical trial.